https://www.selleckchem.com/products/sq22536.html
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment for locally advanced or metastatic -mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier NCT03849768). Patients at 53 sites in China were randomly assigned 11 to receive either aumolertinib (110 mg) or gefitinib (250 mg) once daily. Th
Like
Comment
Share
